Share Email Print

Proceedings Paper

Development of InCVAX as a novel in situ autologous vaccine for metastatic cancers (Conference Presentation)
Author(s): Tomas Hode; Luciano Alleruzzo; Joseph Raker; Samuel Siu Kit Lam; Robert E. Nordquist; Wei R. Chen; Aamr M. Hasanjee
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

A novel method, an in situ autologous whole-cell cancer vaccine (inCVAX), is being developed by Immunophotonics, Inc., for the treatment of metastatic cancers. inCVAX combines phototherapy and immunotherapy to potentially induce a systemic anti-tumor immune response in the hosts. Immunophotonics and its academic partners have spent years conducting nonclinical research, developing CMC techniques and conducting clinical research. In 2015 the company initiated a late-stage (II/III) clinical trial in South America for advanced breast cancer patients. The process of developing the inCVAX approach from a laboratory setting into clinical trials requires significant efforts from a group of dedicated engineers, scientists, and physicians. The growth of the company and its business advances demonstrated the determination of a group of visionary investors, entrepreneurs, and business leaders. This talk will chronicle the milestones of the scientific achievement, medical progress, and business development of Immunophotonics.

Paper Details

Date Published: 27 April 2016
PDF: 1 pages
Proc. SPIE 9709, Biophotonics and Immune Responses XI, 97090I (27 April 2016); doi: 10.1117/12.2216110
Show Author Affiliations
Tomas Hode, Immunophotonics, Inc. (United States)
Luciano Alleruzzo, Immunophotonics, Inc. (United States)
Joseph Raker, Immunophotonics, Inc. (United States)
Samuel Siu Kit Lam, Immunophotonics, Inc. (United States)
Robert E. Nordquist, Immunophotonics, Inc. (United States)
Wei R. Chen, Univ. of Central Oklahoma (United States)
Aamr M. Hasanjee, Univ. of Central Oklahoma (United States)

Published in SPIE Proceedings Vol. 9709:
Biophotonics and Immune Responses XI
Wei R. Chen, Editor(s)

© SPIE. Terms of Use
Back to Top